Applied Finance Capital Management LLC Acquires 6,004 Shares of Gilead Sciences, Inc. $GILD

Applied Finance Capital Management LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 39.9% during the 4th quarter, Holdings Channel reports. The firm owned 21,044 shares of the biopharmaceutical company’s stock after buying an additional 6,004 shares during the period. Applied Finance Capital Management LLC’s holdings in Gilead Sciences were worth $2,583,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA boosted its holdings in shares of Gilead Sciences by 3,763.8% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after purchasing an additional 4,113,999 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Gilead Sciences by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares during the period. First Trust Advisors LP boosted its holdings in shares of Gilead Sciences by 154.3% in the 3rd quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after purchasing an additional 1,874,508 shares during the period. Invesco Ltd. boosted its holdings in shares of Gilead Sciences by 12.0% in the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after purchasing an additional 1,618,453 shares during the period. Finally, Danske Bank A S purchased a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $133,049,000. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total value of $1,291,600.00. Following the sale, the chief executive officer owned 632,567 shares in the company, valued at $81,702,353.72. This represents a 1.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the completion of the sale, the insider owned 128,779 shares in the company, valued at $18,152,687.84. The trade was a 2.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,000 shares of company stock worth $9,238,250 over the last quarter. 0.30% of the stock is currently owned by insiders.

Gilead Sciences Stock Down 1.9%

Shares of GILD stock opened at $129.58 on Friday. The stock’s 50-day simple moving average is $137.76 and its 200-day simple moving average is $133.22. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The firm has a market capitalization of $160.88 billion, a PE ratio of 17.65 and a beta of 0.31. Gilead Sciences, Inc. has a fifty-two week low of $100.23 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company’s revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the company earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities analysts expect that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a $0.82 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Analyst Ratings Changes

A number of equities analysts have recently commented on GILD shares. Rothschild & Co Redburn dropped their target price on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Wells Fargo & Company lifted their target price on Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Cantor Fitzgerald dropped their target price on Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, April 10th. Weiss Ratings upgraded Gilead Sciences from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday. Finally, Leerink Partners dropped their price objective on Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Twenty-four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $157.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.